Business Wire

Trial results of Pradaxa® vs ASA in ESUS published in NEJM

Share

Boehringer Ingelheim today announced full results from the RE-SPECT ESUS® trial, a Phase III randomised, double-blind study investigating the efficacy and safety of Pradaxa® (dabigatran etexilate) versus acetylsalicylic acid (ASA) in preventing recurrent stroke in patients with embolic stroke of undetermined source (ESUS). The results were published in the New England Journal of Medicine (NEJM).1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005334/en/

The trial did not meet its primary endpoint, which was to show a clinically significant difference between dabigatran etexilate and ASA on reducing the risk of a recurrent stroke among post-stroke patients with ESUS. However, a post-hoc analysis showed a treatment effect emerged in favour of dabigatran after one year.1 The safety results from the trial demonstrated that the risk of major bleeding was not significantly different between dabigatran etexilate and ASA.1 A comparable low risk for the most serious bleeding outcomes, such as intracranial haemorrhage, was shown.1

As the first ever comparative trial to investigate dabigatran etexilate versus ASA, the results add to the wealth of evidence supporting the established safety profile of dabigatran etexilate, which has already been demonstrated in its approved indications in the extensive RE-VOLUTION® clinical trial and registry programme.2-24

“The results from RE-SPECT ESUS provide highly interesting information, showing that dabigatran had a similar low risk of major bleeding compared to ASA in this high-risk population of post-stroke patients. This clearly reaffirms the positive risk-benefit profile of dabigatran,” said Dr Waheed Jamal, Corporate Vice President, Head of CardioMetabolic Medicine, Boehringer Ingelheim.

ESUS is a type of cryptogenic stroke, which is when an ischaemic stroke has an unknown cause.25 A stroke is classified as an ESUS when other potential diagnoses have been ruled out.25,26 Overall, one in six ischaemic strokes are classified as ESUS.25 Following an ESUS, most patients are treated with anti-platelet therapy, such as ASA27; however, one in three go on to have a recurrent stroke within five years.28

Pradaxa is not approved in any country for patients with ESUS.

Randomised, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid (ASA) in patients with embolic stroke of undetermined source (RE-SPECT ESUS ® ) 1

RE-SPECT ESUS® was a Phase III, double-blind trial of dabigatran vs ASA for secondary stroke prevention in patients with ESUS and involved 5,390 patients from more than 40 countries. Patients were randomised to receive dabigatran etexilate 150 mg BID, adjusted to 110mg BID for patients above 75 years or with impaired renal function, and a placebo matching ASA 100 mg or ASA 100 mg and a placebo matching dabigatran etexilate. The primary endpoint of the trial was to show a clinically significant difference between dabigatran etexilate and ASA on the risk of a recurrent stroke among post-stroke patients with ESUS.1

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/noac-vs-asa-esus-trial-results-published-nejm

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. It is directed to the international audience outside Germany. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Meike Bausinger
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mundipharma Announces the Licence Extension Submission for Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin) to the European Medicines Agency22.8.2019 02:01:00 EESTPress release

STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has accepted the licence extension submission for these two medicines to treat stage 2 or stage 3 chronic kidney disease (CKD) and albuminuria as an adjunct to standard of care in adults with type 2 diabetes mellitus (T2DM). The submission is based on the results from the landmark Phase III CREDENCE study1 which evaluated the efficacy and safety of canagliflozin versus placebo in this high-risk patient population when used in addition to standard of care. “Chronic kidney disease is a serious complication of type 2 diabetes, which can increase patients’ risk of developing end-stage renal disease and may reduce their life expectancy by several years.” said Dr Vinicius Gomes de Lima, European Medical Affairs Lead, Mundipharma. “If approved, this licence

Triton Digital Releases Webcast Metrics Rankings for the Top Digital Audio Properties for April 201921.8.2019 23:00:00 EESTPress release

Triton Digital®, the global technology and services leader to the digital audio and podcast industry, released today its monthly Webcast Metrics® rankers for April 2019. The global rankers, in addition to the U.S., LATAM, and EMEA regional rankers provide insight into the top-performing streaming audio stations and networks around the world for the month of April. The full results of the Global & Regional Rankers for April 2019 can be found here: https://www.tritondigital.com/resources/monthly-rankers/rankers-archive The Webcast Metrics streaming measurement service is the industry standard for online audio consumption data. It provides credible, validated data that enables audio publishers around the world to analyze the consumption of their audio content by daypart, device type, geography, distribution platform, and more. About Triton Digital Triton Digital® is the global technology and services leader to the digital audio and podcast industry. Operating in more than 40 countries, Tr

Celsius Partners With Tether to Bring USDT its Highest Interest-earning Wallet at 10.53% APR21.8.2019 18:15:00 EESTPress release

Celsius Network (https://celsius.network/), the industry-leading cryptocurrency platform, announces today its partnership with Tether, a stablecoin which pegs its value to the US dollar. The Celsius app now supports the USDT ERC20 stablecoin allowing USDT holders to earn rewards and request loans on a far less volatile asset than other cryptocurrencies. Celsius users can now request a loan issued in USDT, in addition to the existing stablecoins and fiat loan options available through Celsius, at rates as low as 4.95% APR. The company currently offers interest income of 8.1% APR on USDT deposits and 10.53% when paid in CEL tokens. At the same time, using stablecoins reduces capital costs, allowing Celsius to offer loans at a lower rate. Celsius has achieved notable milestones in the past year to drive the decentralization of traditional financial structures: Over $2.2 billion worth of coin loans originated since July 2018 Over $350 million AUM in customer deposits and collateral from lo

The World's First 5nm Generation AI Chip is Taped Out - TeraPixel Technologies, Inc.21.8.2019 17:00:00 EESTPress release

TeraPixel Technologies Inc. (Representative: Naoki Kawahara) taped out “Extrixa Processor” as the first deep-learning AI product on March 8, 2019 as the world's first chip that uses TSMC 5nm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005023/en/ Picture of Mechanical Sample for 5nm Deep Learning AI Processor (Photo: Business Wire) Wafer equipped with ASIC implemented in the world's most advanced process rolls out on August 25 and is scheduled to be available in early September after assembly testing. This 5nm process will be used to check the core performance and power consumption since SRAM cells were not yet prepared at the time of tape-out in March. In the first quarter of 2020, we will tape out the second version with the same functions as the product version with SRAM and other functional blocks. TeraPixel has R & D technology for massively parallel processors with many cores, aiming for the world's highest le

Cummins President and COO Rich Freeland Retiring21.8.2019 16:00:00 EESTPress release

Cummins Inc. (NYSE: CMI) announced today that President and COO, Rich Freeland will retire after forty years of service with Cummins. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005396/en/ Rich Freeland (Photo: Business Wire) As part of Cummins’ successions plans, the following leadership appointments are also taking place, all of which are effective October 15. Distribution President Tony Satterthwaite will succeed Freeland as President and COO. Components President Tracy Embree will succeed Satterthwaite as Distribution Business President. Chief Technical Officer Jennifer Rumsey will succeed Embree as Components Business President. Jim Fier will succeed Rumsey as Chief Technical Officer. “I want to personally thank Rich for his many contributions to Cummins and his friendship and support over the 25 years I have known and worked with him,” said Tom Linebarger, Chairman and CEO, Cummins Inc. “He is one of the most

Open Web Automation (OWA): How logi.cals Reinvents the World of PLC Programming and Engineering21.8.2019 15:32:00 EESTPress release

"Never Touch a Running System" is still a central unwritten law in machine and plant engineering. Once an application operates, function and programming are changed as little as possible. This is however no longer up-to-date, as companies with this approach in the automation and engineering process are increasingly lagging behind the requirements for flexibility, time-to-market and quality. Dynamizing the adaptation of the programming of a machine or plant to new tasks requires innovative engineering tools and environments. Open Web Automation (OWA) is logi.cals' answer as a flexible and dynamically evolving automation system that guides the user: from the plant model to configuration, engineering, automated testing, simulation, visualization and beyond. Supporting numerous open standards such as OPC UA, Automation ML or the IEC61131 languages, OWA is the platform for open automation applications. OWA is a modular cloud architecture, which with its browser-based core components, numero

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom